Shares of Moderna (NASDAQ:MRNA) had been leaping 7.4% greater as of three:42 p.m. EDT on Wednesday. The acquire got here after the corporate introduced that it gained a brand new deal to produce its COVID-19 vaccine to Israel for 2022.
Moderna did not reveal what number of doses are included in its newest settlement with Israel. Nonetheless, Israeli information group Ynet reported earlier this week that Israel was shopping for 7.2 million doses of the corporate’s COVID-19 vaccine for round 0.5 billion shekels, which equates to roughly $150 million.
Why did the market cap for the biotech inventory rise by near $5 billion on a brand new provide deal price solely a fraction of that quantity? Buyers may merely be overreacting to Moderna’s excellent news.
Nonetheless, it is necessary to notice that that is the primary agency order that the corporate has acquired to produce COVID-19 vaccine doses for subsequent yr. Israel beforehand ordered 10 million doses of Moderna’s vaccine for 2021. A big order for subsequent yr may bode nicely for the corporate’s prospects of successful provide agreements with different international locations that are not a lot decrease than its 2021 offers.
Israel additionally retains an choice to purchase doses of one of many new variant-specific COVID-19 vaccine candidates that Moderna is creating pending regulatory approval.
Buyers will watch carefully now to see if different international locations start putting orders for Moderna’s vaccine to be used subsequent yr. The inventory may transfer even greater if the corporate traces up main provide agreements with the U.S. and/or the European Union.
This text represents the opinion of the author, who could disagree with the “official” advice place of a Motley Idiot premium advisory service. We’re motley! Questioning an investing thesis — even one in every of our personal — helps us all suppose critically about investing and make selections that assist us turn out to be smarter, happier, and richer.